EA200400774A1 - Лечение атрофии мышц с помощью селективных модуляторов андрогенового рецептора - Google Patents

Лечение атрофии мышц с помощью селективных модуляторов андрогенового рецептора

Info

Publication number
EA200400774A1
EA200400774A1 EA200400774A EA200400774A EA200400774A1 EA 200400774 A1 EA200400774 A1 EA 200400774A1 EA 200400774 A EA200400774 A EA 200400774A EA 200400774 A EA200400774 A EA 200400774A EA 200400774 A1 EA200400774 A1 EA 200400774A1
Authority
EA
Eurasian Patent Office
Prior art keywords
help
treatment
androgen receptor
muscle atrophy
selective modulators
Prior art date
Application number
EA200400774A
Other languages
English (en)
Other versions
EA007921B1 (ru
Inventor
Митчелл С. Стейнер
Карен А. Веверка
Джеймс Т. Долтон
Дуэйн Д. Миллер
Original Assignee
Джи Ти Икс, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи Ти Икс, ИНК. filed Critical Джи Ти Икс, ИНК.
Publication of EA200400774A1 publication Critical patent/EA200400774A1/ru
Publication of EA007921B1 publication Critical patent/EA007921B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение обеспечивает способ лечения субъекта, страдающего от заболевания, связанного с атрофией мышц; способ профилактики заболевания, связанного с атрофией мышц у субъекта; способ лечения, профилактики, подавления, ингибирования или уменьшения случаев потери мышц у субъекта, страдающего от заболевания, связанного с атрофией мышц; способ лечения, профилактики, ингибирования, уменьшения или подавления атрофии мышц у субъекта, страдающего от заболевания, связанного с атрофией мышц; и/или способ лечения, профилактики, ингибирования, уменьшения или подавления катаболизма мышечного белка у субъекта, страдающего от заболевания, связанного с атрофией мышц, путем введения субъекту (SARM) соединения как селективного модулятора андрогенового рецептора и/или его аналога, производного изомера, метаболита, фармацевтически приемлемой соли, фармацевтического продукта, гидрата, N-оксида или любой их комбинации, как определено в настоящем изобретении.Отчет о международном поиске был опубликован 2004.04.01.
EA200400774A 2001-12-06 2002-12-05 Лечение атрофии мышц с помощью селективных модуляторов андрогенового рецептора EA007921B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33618501P 2001-12-06 2001-12-06
PCT/US2002/036147 WO2003049675A2 (en) 2001-12-06 2002-12-05 Treating muscle wasting with selective androgen receptor modulators

Publications (2)

Publication Number Publication Date
EA200400774A1 true EA200400774A1 (ru) 2004-12-30
EA007921B1 EA007921B1 (ru) 2007-02-27

Family

ID=23314937

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400774A EA007921B1 (ru) 2001-12-06 2002-12-05 Лечение атрофии мышц с помощью селективных модуляторов андрогенового рецептора

Country Status (21)

Country Link
US (1) US7547728B2 (ru)
EP (2) EP1463497B1 (ru)
JP (2) JP4605557B2 (ru)
KR (1) KR100767317B1 (ru)
CN (1) CN1617715B (ru)
AT (1) ATE526959T1 (ru)
AU (1) AU2002364949C1 (ru)
BR (1) BR0215115A (ru)
CA (1) CA2469340A1 (ru)
CY (1) CY1112509T1 (ru)
DK (1) DK1463497T3 (ru)
EA (1) EA007921B1 (ru)
ES (1) ES2372929T3 (ru)
GE (1) GEP20063984B (ru)
HK (1) HK1068102A1 (ru)
HR (1) HRP20040588A2 (ru)
IL (2) IL162340A0 (ru)
MX (1) MXPA04005519A (ru)
PT (1) PT1463497E (ru)
TW (1) TWI339118B (ru)
WO (1) WO2003049675A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493403B2 (en) 2000-08-24 2016-11-15 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US8008348B2 (en) * 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7253210B2 (en) * 2002-10-15 2007-08-07 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
BR0215115A (pt) * 2001-12-06 2005-04-19 Gtx Inc Tratamento de perda muscular com moduladores de receptores de androgênio seletivos
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
WO2003065992A2 (en) 2002-02-07 2003-08-14 Gtx, Inc. Treating benign prostate hyperplasia with sarms
EP2266577B8 (en) * 2002-02-28 2015-01-21 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
MXPA04009460A (es) * 2002-02-28 2006-04-27 Univ Tennessee Res Foundation Moduladores receptores de androgeno selectivo multi-sustituidos y metodos de uso de los mismos.
US20060064767A1 (en) * 2002-08-19 2006-03-23 Gen Sobue Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
WO2004035739A2 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
CN100462353C (zh) * 2003-06-27 2009-02-18 奥赖恩公司 用作雄激素受体调节剂的丙酰胺衍生物
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
DE602004026583D1 (de) * 2003-06-27 2010-05-27 Orion Corp Als androgenrezeptormodulatoren geeignete propionamidderivate
CN101721402B (zh) * 2003-10-14 2013-03-13 田纳西大学研究基金会 用选择性雄激素受体调节剂治疗骨相关病症
CA2522874A1 (en) * 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
EP1737813A1 (en) * 2004-04-13 2007-01-03 Warner-Lambert Company LLC Androgen modulators
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
BRPI0511308B8 (pt) * 2004-06-07 2021-05-25 Univ Tennessee Res Found moduladores seletivos receptores de androgênio e seus métodos de uso
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US7601725B2 (en) 2004-07-16 2009-10-13 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as Aurora kinase inhibitors
US7655700B2 (en) * 2005-08-25 2010-02-02 Michigan State University Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles
AU2006285026B2 (en) * 2005-08-31 2012-08-09 University Of Tennessee Research Foundation Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
PT2038252T (pt) * 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
PL2054049T3 (pl) 2006-08-24 2016-11-30 Podstawione acyloanilidy i sposoby ich stosowania
DK2176220T3 (da) 2007-08-07 2013-06-10 Takeda Pharmaceutical Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EP2205552B1 (en) * 2007-09-11 2018-02-28 GTx, Inc. Crystalline polymorph of the selective androgen modulators (r) or (s)-n-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
CA2709677C (en) 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
CA2800109C (en) 2010-05-20 2020-06-30 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
CA2838275C (en) 2011-06-06 2021-08-10 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
WO2013078372A1 (en) * 2011-11-23 2013-05-30 University Of Iowa Research Foundation Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
EP2834216A1 (en) * 2012-04-04 2015-02-11 Catylix Inc. Selective androgen receptor modulators
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
MX2015000572A (es) 2012-07-13 2015-09-23 Gtx Inc Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP2015071549A (ja) * 2013-10-02 2015-04-16 株式会社ファンケル アトロジン−１抑制剤
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
CN106999453A (zh) * 2014-10-16 2017-08-01 Gtx公司 使用sarm治疗泌尿病症的方法
KR101919081B1 (ko) * 2017-05-11 2018-11-16 (주)녹십자웰빙 인간 태반 추출물을 유효성분으로 포함하는 근 위축증 또는 근육감소증의 예방 또는 치료용 및 근육 기능 개선용 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
US4336505A (en) * 1980-07-14 1982-06-22 John Fluke Mfg. Co., Inc. Controlled frequency signal source apparatus including a feedback path for the reduction of phase noise
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US4633025A (en) 1985-04-15 1986-12-30 Miles Laboratories, Inc. Method for preparing (+)R-2-methyl-hexane-1,2-diol
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5847076A (en) * 1993-05-20 1998-12-08 Board Of Regents, The University Of Texas System Regulators of the proteasome
EP0748220A4 (en) 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6995284B2 (en) * 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
WO1998053826A1 (en) * 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
US6019957A (en) * 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
AU775928B2 (en) 1999-10-14 2004-08-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
CZ20021340A3 (cs) 1999-10-19 2002-08-14 Nobex Corporation Způsoby asymetrické přípravy enantiomerů acylanilidů, jejich derivátů a meziproduktů pro uvedené přípravy
CZ20021434A3 (cs) 1999-10-27 2002-11-13 Nobex Corporation Způsob přípravy v podstatě čistého enantiomeru acylanilidu
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
CZ20024214A3 (cs) 2000-06-28 2003-04-16 Bristol-Myers Squibb Company Selektivní androgen receptorový modulátor, způsob jeho identifikace, jeho konstrukce a použití
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
CN1230418C (zh) * 2000-08-24 2005-12-07 田纳西大学研究公司 选择性雄激素受体调节剂及其使用方法
IL154425A0 (en) * 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
BR0215115A (pt) * 2001-12-06 2005-04-19 Gtx Inc Tratamento de perda muscular com moduladores de receptores de androgênio seletivos
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493403B2 (en) 2000-08-24 2016-11-15 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs

Also Published As

Publication number Publication date
IL162340A (en) 2013-09-30
CA2469340A1 (en) 2003-06-19
GEP20063984B (en) 2006-12-11
CY1112509T1 (el) 2015-12-09
JP2010254707A (ja) 2010-11-11
BR0215115A (pt) 2005-04-19
EP1463497A2 (en) 2004-10-06
EP1463497B1 (en) 2011-10-05
DK1463497T3 (da) 2012-01-30
WO2003049675A3 (en) 2004-04-01
ES2372929T3 (es) 2012-01-27
TW200410674A (en) 2004-07-01
AU2002364949A1 (en) 2003-06-23
HRP20040588A2 (en) 2004-10-31
EP1463497A4 (en) 2007-11-14
US20040087557A1 (en) 2004-05-06
EA007921B1 (ru) 2007-02-27
WO2003049675A2 (en) 2003-06-19
EP2289503B1 (en) 2016-06-29
JP2005516002A (ja) 2005-06-02
HK1068102A1 (en) 2005-04-22
TWI339118B (en) 2011-03-21
PT1463497E (pt) 2011-12-20
AU2002364949C1 (en) 2008-05-29
CN1617715B (zh) 2010-05-12
CN1617715A (zh) 2005-05-18
IL162340A0 (en) 2005-11-20
ATE526959T1 (de) 2011-10-15
KR100767317B1 (ko) 2007-10-17
MXPA04005519A (es) 2005-06-20
EP2289503A2 (en) 2011-03-02
KR20050044714A (ko) 2005-05-12
JP4605557B2 (ja) 2011-01-05
US7547728B2 (en) 2009-06-16
EP2289503A3 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
EA200400774A1 (ru) Лечение атрофии мышц с помощью селективных модуляторов андрогенового рецептора
DK1459749T3 (da) (S,S)-reboxetin til behandling af inkontinens
MXPA03007140A (es) Derivados de carbolina.
BR0209511B1 (pt) composiÇço herbicida sinergÍstica, e, mÉtodo para controlar vegetaÇço indesejÁvel.
DK1292335T3 (da) Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II)
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
ZA200503967B (en) Agent for preventing or treating neuropathy
SE9900100D0 (sv) New compounds
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
MXPA03003912A (es) Tratamientos nuevos para el sindrome de piernas inquietas.
NO20001870L (no) Ny fremgangsmÕte for behandling
BR0202519B1 (pt) métodos para tratamento de material de madeira e para tratamento microbicida de material de madeira.
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
FI20010356A (fi) Hissiryhmän ohjausmenetelmä
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
MY122838A (en) Treating allergic and inflammatory conditions
DK3103443T3 (da) Fremgangsmåde til behandling af primær søvnforstyrrelse
EP1448193A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS
DK1000046T3 (da) Piperazinderivater, der er aktive på den nedre urinvejskanal
AU2002320352A1 (en) Methods for treating or preventing sclerotic disorders using cd2-binding agents
HU0201394D0 (ru)
FI20022150A (fi) Menetelmä kuonan käsittelemiseksi
EP1458694A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU